Search results

Found 5,000 pages
AUTHOR: Kevin Grogan

Your search yielded no results

  • Check if your spelling is correct.
  • Remove quotes around phrases to search for each word individually. bike shed will often show more results than "bike shed".
  • Consider loosening your query with OR. bike OR shed will often show more results than bike shed.

Teva sales forecast disappoints analysts

Shares in Teva Pharmaceutical Industries have taken a hit after it unveiled 2013 financial forecasts that were below analyst estimates. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/teva_sales_forecast_disappoints_analysts_976115

FDA approves Avastin for ovarian cancer

Roche has garnered a new indication for Avastin from US regulators, this time in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/fda_approves_avastin_for_ovarian_cancer_1002770

Bayer to buy China's Dihon Pharma

Bayer is to buy Dihon Pharmaceutical Group Co of China, expanding the German group's footprint in a "key growth country". - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/bayer_to_buy_chinas_dihon_pharma_1001594

Novartis creates 100 jobs in Ireland

Novartis is expanding its presence in Ireland by setting up a  business services centre in Dublin. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/novartis_creates_100_jobs_in_ireland_1004791

CHMP backs Almirall lung drug combo

Advisors to the European Medicines Agency have recommended approval of Almirall’s Duaklir, a combination therapy for chronic obstructive pulmonary disease that it is in the process of being sold to AstraZeneca. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/chmp_backs_almirall_lung_drug_combo_1002535

Oxford BioMedica expands Pfizer pact

Oxford BioMedica has signed an amendment to broaden its licensing agreement with Pfizer regarding the development of therapeutics which target the company’s 5T4 tumour antigen for the treatment of cancer. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/oxford_biomedica_expands_pfizer_pact_981103

Watson launches generic Actos

Having sued the Food and Drug Administration in the summer, Watson Pharmaceuticals has launched its generic versions of Takeda's blockbuster diabetes drug Actos in the USA which have received the agency's final approval. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/watson_launches_generic_actos_976357

Second breakthrough status for Roche immunotherapy

The US Food and Drug Administration has granted Roche granted a second breakthrough therapy designation for its investigational anti-PDL1 cancer immunotherapy, this time in lung cancer. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/second_breakthrough_status_for_roche_immunotherapy_970973

Skyepharma's Flutiform in COPD trials

The UK’s Skyepharma says that partner Mundipharma has commenced an international clinical trial of the firms’ asthma drug Flutiform for the treatment of chronic obstructive pulmonary disease.  - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/skyepharmas_flutiform_in_copd_trials_1005720

Over 800 jobs to go at B-MS

Bristol-Myers Squibb is the latest drugmaker to announce major lay-offs and reports suggest  that 3% of its global workforce could be cut. - News - PharmaTimes

by Kevin Grogan

www.pharmatimes.com/news/over_800_jobs_to_go_at_b-ms_982365

Latest jobs

View all

What job are you looking for?

This field is required.

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download